

Literature review on DBLMSP and DBLMSP2 in *Plasmodium*

November 10, 2022

Conventions

Throughout the report I refer to DBLMSP and DBLMSP2 as **DBs**.

All gene names use the stable IDs from PlasmoDB release 53.

Important references are highlighted in the bibliography.

1 Current state of knowledge relevant to DBs

1.1 Genomic location and domain structure of DBs

In *P. falciparum*, DBLMSP and DBLMSP2 are two genes located 16kbp apart on chromosome 10 (DBLMSP: Pf3D7_10_v3:1,412,641..1,416,363(+); DBLMSP2: Pf3D7_10_v3:1,432,498..1,434,786(+)). They are part of a set of 8 tandemly arrayed genes spanning 32kbp on chromosome 10 that all share an N-terminal ‘NLRNA/G’ sequence [55]. [55] call them ‘MSP3-like’, and proposed renaming them MSP3.1-MSP3.8. In this system MSP3.4 and MSP3.8 are the names for what is now stably referred to as DBLMSP and DBLMSP2, respectively. Six of the eight genes, including DBLMSP and DBLMSP2, possess a polymorphic C-terminal domain called SPAM ([36]; Pfam: PF07133). In MSP3 (MSP3.1 in the MSP3-like classification), SPAM was found to mediate protein oligomerisation [18]. The genes GLURP and LSA-1 are located 5’ and 3’ of the MSP3-like gene cluster, respectively.

In contrast to the other MSP3-like genes, DBs also possess a Duffy-Binding Like (DBL) domain (Pfam: PF05424), located between the N-terminal NLR sequence and C-terminal SPAM. DBL is named after the

initial discovery that *Plasmodium vivax* requires the so-called Duffy antigen/chemokine receptor (DARC) on human red-blood cells for cell invasion [37]. In *P. vivax* and *P. knowlesi*, a gene called Duffy Binding Protein (DBP) is responsible for binding DARC.

1.2 DBL domains in *P. falciparum*

In addition to the DBs, the DBL domain is present in a number of other *P. falciparum* (*Pf*) proteins. EBA175 was first identified as a protein mediating RBC invasion via binding to the RBC receptor glycophorin A (GYPA) [42], a RBC surface glycoprotein ('glyco' means sugars attached). EBA175 binding requires a sialic acid (e.g. Neu5Ac) attached to GYPA [42], and antibodies raised against EBA175 inhibit merozoite invasion of RBCs [54]. EBA175 contains two tandemly arrayed DBL domains [1] called F1 and F2 that mediate GYPA binding [61]. A number of genes paralogous to EBA175 exist that also have tandem F1/F2 DBL domains: EBA140, EBA165, EBA181, EBL1 (fig. 1; [2]). EBA140 also mediates merozoite invasion of RBCs [35] by binding to the glycophorin C receptor linked to sialic acid [31]. EBA165 is functional in all *Laverania* species but is inactivated in *Pf* and is thus a pseudogene [50]. EBL1 and EBA181 are less well understood. EBL1 may bind to glycophorin B [26], and EBA181 binds RBCs but the receptor is unknown [16].

The presence of multiple EBA paralogs is thought to mediate functional redundancy, allowing merozoites from different strains to invade RBCs with different surface receptors (e.g. lacking glycophorin A and B [22]) or differently modified surface receptors (e.g. with sialic acid removed [39, 57]). Alternative use of different EBAs for invasion was also shown to be epigenetically mediated for EBA-140, with expression switched on or off across isogenic subclones [8]. Another paralogous family of proteins, the reticulocyte-binding homologs (RH), is located in the same apical organelles as EBAs (rhoptries and micronemes). RHs are also involved in RBC invasion and displays functional redundancy [19]. RHs and EBAs are thought to function cooperatively in RBC invasion [32]. Because both protein families are recognised by the immune system, alternative invasion pathways likely provide adaptability against immune system targeting of specific proteins [66].

DBL domains are also found in the *var* genes, a family of paralogs specific to the subgenus *Laverania* [45, 44] (of which *Pf* is a member, but not *P. vivax*). *var* genes are mostly located in chromosome subtelomeres, with 60




Figure 1: DBL domains in the erythrocyte-binding like gene family. F1 and F2 are tandem DBL domains homologous to *P. vivax* DBL. All genes except EBL1 possess a conserved C-terminal cysteine rich domain. ID mapping: EBA181(*jesebl*), EBA165(*pebl*), EBA140(*baeb1*). Source: [2].

copies in the *Pf* genome [59, 15]. During the ring stage of the intraerythrocytic cycle (IEC), *Pf* expresses only one or a few *var* genes at a time, and during the schizont and trophozoite stages of the IEC, a single *var* protein product (called *PfEMP1*) is found exported at the surface of the iRBC [7]. The 5' end of *var* genes contains multiple DBL and CIDR domains mediating adherence to other cells (fig. 2). PfEMP1 allows iRBC to bind to uninfected red blood cells (rosetting), endothelial cell receptors in tissues, and to platelets enabling iRBC clumping [38]. The specific combination of DBL and CIDR domains determines the set of bound human receptors and is associated with malaria disease severity [TODO citations]. Different domain combinations are produced via meiotic recombination during sexual reproduction [58], but also by non-allelic recombination [14] during mitosis [10] (and thus during a single infection). Recombination occurs in a structured way between subgroups of *var* genes based on genomic context (subtelomeric, central), gene orientation and flanking non-coding sequence [29]. Of all the DBL/CIDR domains, only DBL- α is found in every *var* gene [56].

PfEMP1 is recognised by the human immune system [TODO: cite]. *Pf* evades immune system recognition and clearance by switching which *var* gene is expressed during the course of infection [52]. [TODO epigenetically mediated].

1.3 Biological function of DBs

1.3.1 DB localisation and RBC binding

DBLMSP is expressed at the late schizont and merozoite stages and localises to the merozoite surface [65]. [65] showed that COS7 (monkey-derived) cells made to express the DBL and SPAM domains of DBLMSP bound RBCs. Binding was abolished by treating RBCs with trypsin or neuraminidase or by adding immune sera from DBLMSP-immunised mice. Using ELISA, [65] also showed recombinant DBL and SPAM domains were both bound by human immune sera from malaria-exposed, but not malaria-naive, individuals. This suggests DBLMSP is involved in RBC binding by merozoites. However, *in vitro* RBC invasion is only reduced by 25% in the presence of high levels of anti-DBLMSP antibodies([53] Fig. 4B), and RBC invasion efficiency is not reduced in DBLMSP knock-out parasite lines [53, 9], showing DBLMSP is not essential for RBC invasion.

[24] find DBLMSP2 is expressed on the surface of schizonts and mero-




Figure 2: DBL domains in the *var* gene family. *var* genes have a N-terminal segment (NTS), transmembrane (TM) domain and acidic terminal segment (ATS), and *var* types are assigned by combination of DBL and CIDR domains. The left-hand panel gives counts of *var* types in the *Pf* 3D7 genome by promoter type (*UpsA-UpsE*). The bottom panel lists bound human proteins. Source: [28].

zoites using anti-DBLMSP2 antibodies, and that full-length DBLMSP2 and the DBL domain only bind to RBCs. There are potential caveats to these results. In contrast to [65], who expressed DBLMSP on COS7 cells and assayed RBC binding, [24] added purified DBLMSP2 to RBCs together with *Pf* post-invasion culture supernatant, so the DBLMSP2 in pulldowns could have been in complex with other *Pf* proteins binding to RBCs. [24] also do not find that DBLMSP binding to RBCs is trypsin or neuraminidase sensitive, whereas [65] do. Finally, Gavin Wright and Cecile Crosnier at the Sanger Institute could not replicate DBLMSP2 binding to RBCs (unpublished, personal communication).

1.3.2 DBLMSP2 and gametocytogenesis

DBLMSP2 transcripts are present at very low levels in bulk RNA-seq of clinical and laboratory isolates ([46] Sup. Table S3, [3]). Using immunofluorescent labeling of DBLMSP2, [3] showed that DBLMSP2 is only present on the surface of a minority of schizonts (fig. 3). This is consistent with repressive chromatin factors being found at the DBLMSP2 locus: histone mark H3K9me3 [33] and heterochromatin protein 1 (HP1; [13]). These marks are not widespread in the genome and are typically associated with clonally variant expression of virulence gene families (e.g. *var*, *rif*, *stevor*, *clag* [33]). In *Pf*, HP1 epigenetically regulates both the single, mutually exclusive expression of *var* genes and sexual commitment via the induction of the *ap2-g* transcription factor [5], which is essential for sexual differentiation of *Pf* into gametocytes [27]. HP1 forms a complex with the *PfGDV1* protein [12], another early marker of gametocytogenesis [11]. Consistent with this, [12] found that conditional activation of *PfGDV1* induces *ap2-g* expression and gametocytogenesis, likely by antagonising HP1-based repression. Remarkably, DBLMSP2 is one of the 8 genes induced by *PfGDV1* ([12] Fig. 2). However, in two other studies DBLMSP2 did not appear as part of the transcriptional signature of sexual commitment defined using single-cell RNA-seq ([49] Supplementary Table 3; [6] Supplementary File 2). It is thus unclear still whether DBLMSP2 plays a role in gametocytogenesis.

1.3.3 DBLMSP2 and drug resistance

DBLMSP2 has also been implicated in drug resistance. A GWAS study using SNP array genotyping found variants in DBLMSP2 associated with resistance

to the antimalarial halofantrine [63]. [63] functionally validated the association by showing that episomal (plasmid-mediated) DBLMSP2 overexpression increases resistance to halofantrine and structurally related compounds (mefloquine and lumefantrine), and that *Pf* strains with higher DBLMSP2 copy-number are also more resistant. Given that DBLMSP and DBLMSP2 occur in tandem and can share sequence [34], I think WGS-based CNV quantification is required to validate cross-strain CNV differences in DBLMSP2. Subsequently, [64] found that knocking-out DBLMSP2 reduced IC_{50} (drug concentration giving a 50% parasite growth reduction) to these three antimalarials by about 50%, and that a specific SNP (C591S) in the SPAM domain approximately doubles IC_{50} for all three antimalarials.

1.3.4 DB complex formation

All six ‘MSP3-like’ proteins (which includes the DBs) localise to the merozoite surface [55]. Despite this, all ‘MSP3-like’ proteins lack transmembrane domains and GPI anchors characteristic of membrane-anchored proteins. One ‘MSP3-like’ protein, MSP6, was found to occur bound to GPI-mediated membrane-anchored MSP1 [62]. This was also found for another merozoite surface protein, MSP7 [47]. Subsequently, [30] found that DBs are also found in complex with MSP1. MSP1 is the most abundant merozoite surface protein [17] and is proteolytically processed into four, non-covalently linked subunits during merozoite maturation. Upon merozoite entry into RBCs, the MSP1 complex is cleaved by the PfSUB2 protease [23], leaving the GPI-anchor MSP1 fragment bound to the merozoite surface while the rest is shed [4, 23]. Antibodies against MSP1 block invasion [4] and are associated with protection from malaria [43]. AMA1, a microneme protein involved in merozoite reorientation post RBC attachment and a major vaccine target, is also shed following PfSUB2 cleavage [23]. Interestingly, EBA175 is also shed post-merozoite invasion via proteolytic cleavage by the PfROM4 protein [40]. Subsequent work showed shed EBA175 mediates uninfected RBC clustering via its two tandem DBL domains, and that RBC clustering enhances merozoite reinfection and immune system evasion [48] (see fig. 4 for an illustrative model).





Figure 3: DBLMSP2 is expressed in a subset of schizonts. (A) DAPI (parasite nuclear DNA) and DBLMSP2 immunofluorescent staining with anti-DBLMSP2 antibodies shows DBLMSP2 is present at the surface of a small number of schizonts in three independent cultured isolates (HB3, K1, D6). (B) The HB3 parasite line has the highest fraction of DBLMSP2-positive schizonts. Source: [3]




Figure 4: EBA175 shed from merozoites post RBC invasion mediates RBC clustering. Model from [48]. The two DBL domains from EBA175 mediate RBC clustering by binding to GYPA on the RBC surface. RBC clustering reduced antibody-based (anti-AMA1 and anti-RH5) growth inhibition (illustrated in d) and enhanced parasite growth (illustrated in e).

1.3.5 Immune system interactions

[55] find IgGs in immune serum from people in malaria-endemic Senegal react against a conserved C-terminal region in all six ‘MSP3-like’ proteins, suggesting cross-reactive immunity to all can arise.

No RBC binding partners for DBs have been identified to date, and conflicting evidence exists regarding what kind of RBCs DBs bind ([65] vs [24]). Further, from personal communication, Cecile Crosnier and Gavin Wright did not observe DB binding to RBCs.

1.4 Genetic diversity of DBs

2 Questions of interest around DBs

δ : doable ϵ : uncertain

2.1 Biological function

1. [δ] What is the sequence and structure relationship between DBL domain in DBs and other *Pf* DBL domains? (see [51] for an analysis of DBL homology blocks, with MEME motifs, showing parallel between EBA-175 and VAR2CSA DBL structures (Fig.5))
2. [ϵ] Can we identify putative human protein interactants, can we dock DBs to them, and can we evaluate goodness of fit compared to known DBL-human protein interactions?
3. [ϵ] Can we find putative structural interactants expressed in human cell types likely to be in DB environment when DBs are expressed? (e.g. bone marrow for DBLMSP2 in early gametocytes)
4. [δ] How often are DBs not functional (nonsense mutations) in natural pops, and is there a diff. between DBLMSP and DBLMSP2? (Note premature stop codons are known in DBLMSP: [60]; [41] Table 1)
5. [δ] What is the phylogenetic distribution of DBs?

2.2 Location of polymorphisms

1. [δ] Do we see conserved/hypervariable sites at the DNA level?
2. [δ] Can we map polymorphisms onto DB structures and identify structurally conserved or variable regions? (BioStruct can do this [20], see [21] for examples in *Pf*)

2.3 Gene conversion and recombination

1. [ϵ] Can we identify and quantify gene conversion events between DBs? (Note, could maybe also do this in tandemly arrayed genes clag 3.1 and clag 3.2, this has been observed in [25])

2.4 Drug resistance

1. [δ] Is the drug resistance SNP in DBLMSP2 SPAM domain found in DBLMSP sequences (or other 'MSP3-like' proteins with SPAM domains)?

References

- [1] J H Adams et al. “A family of erythrocyte binding proteins of malaria parasites”. In: *Proceedings of the National Academy of Sciences* 89.15 (1992), pp. 7085–7089. ISSN: 0027-8424. DOI: 10.1073/pnas.89.15.7085. eprint: <https://www.pnas.org/content/89/15/7085.full.pdf>. URL: <https://www.pnas.org/content/89/15/7085>.
- [2] John H. Adams et al. “An expanding ebl family of Plasmodium falciparum”. In: *Trends in Parasitology* 17.6 (June 2001), pp. 297–299. DOI: 10.1016/s1471-4922(01)01948-1. URL: [https://doi.org/10.1016/s1471-4922\(01\)01948-1](https://doi.org/10.1016/s1471-4922(01)01948-1).
- [3] Alfred Amambua-Ngwa et al. “Population Genomic Scan for Candidate Signatures of Balancing Selection to Guide Antigen Characterization in Malaria Parasites”. In: *PLoS Genetics* 8.11 (Nov. 2012). Ed. by Ananias A. Escalante, e1002992. DOI: 10.1371/journal.pgen.1002992. URL: <https://doi.org/10.1371/journal.pgen.1002992>.
- [4] M J Blackman et al. “A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.” en. In: *Journal of Experimental Medicine* 172.1 (July 1990), pp. 379–382. ISSN: 0022-1007, 1540-9538. DOI: 10.1084/jem.172.1.379. URL: <https://rupress.org/jem/article/172/1/379/24831/A-single-fragment-of-a-malaria-merozoite-surface> (visited on 09/04/2021).
- [5] Nicolas M.B. Brancucci et al. “Heterochromatin Protein 1 Secures Survival and Transmission of Malaria Parasites”. In: *Cell Host & Microbe* 16.2 (Aug. 2014), pp. 165–176. DOI: 10.1016/j.chom.2014.07.004. URL: <https://doi.org/10.1016/j.chom.2014.07.004>.
- [6] Nicolas M.B. Brancucci et al. “Probing Plasmodium falciparum sexual commitment at the single-cell level”. In: *Wellcome Open Research* 3 (Oct. 2018), p. 70. DOI: 10.12688/wellcomeopenres.14645.4. URL: <https://doi.org/10.12688/wellcomeopenres.14645.4>.
- [7] Qijun Chen et al. “Developmental selection of var gene expression in Plasmodium falciparum”. In: *Nature* 394.6691 (July 1998), pp. 392–395. DOI: 10.1038/28660. URL: <https://doi.org/10.1038/28660>.

- [8] Alfred Cortés et al. “Epigenetic Silencing of *Plasmodium falciparum* Genes Linked to Erythrocyte Invasion”. In: *PLoS Pathogens* 3.8 (Aug. 2007). Ed. by Joe D Smith, e107. DOI: 10.1371/journal.ppat.0030107. URL: <https://doi.org/10.1371/journal.ppat.0030107>.
- [9] Cécile Crosnier et al. “Binding of *Plasmodium falciparum* Merozoite Surface Proteins DBLMSP and DBLMSP2 to Human Immunoglobulin M Is Conserved among Broadly Diverged Sequence Variants”. In: *Journal of Biological Chemistry* 291.27 (July 2016), pp. 14285–14299. DOI: 10.1074/jbc.m116.722074. URL: <https://doi.org/10.1074/jbc.m116.722074>.
- [10] Michael F. Duffy et al. “Ectopic Recombination of a Malaria var Gene during Mitosis Associated with an Altered var Switch Rate”. In: *Journal of Molecular Biology* 389.3 (June 2009), pp. 453–469. DOI: 10.1016/j.jmb.2009.04.032. URL: <https://doi.org/10.1016/j.jmb.2009.04.032>.
- [11] Saliha Eksi et al. “*Plasmodium falciparum* Gametocyte Development 1 (Pfgdv1) and Gametocytogenesis Early Gene Identification and Commitment to Sexual Development”. In: *PLoS Pathogens* 8.10 (Oct. 2012). Ed. by Thomas J. Templeton, e1002964. DOI: 10.1371/journal.ppat.1002964. URL: <https://doi.org/10.1371/journal.ppat.1002964>.
- [12] Michael Filarsky et al. “GDV1 induces sexual commitment of malaria parasites by antagonizing HP1-dependent gene silencing”. In: *Science* 359.6381 (Mar. 2018), pp. 1259–1263. DOI: 10.1126/science.aan6042. URL: <https://doi.org/10.1126/science.aan6042>.
- [13] Sabine A. Fraschka et al. “Comparative Heterochromatin Profiling Reveals Conserved and Unique Epigenome Signatures Linked to Adaptation and Development of Malaria Parasites”. In: *Cell Host & Microbe* 23.3 (Mar. 2018), 407–420.e8. DOI: 10.1016/j.chom.2018.01.008. URL: <https://doi.org/10.1016/j.chom.2018.01.008>.
- [14] Lúcio H. Freitas-Junior et al. “Frequent ectopic recombination of virulence factor genes in telomeric chromosome clusters of *P. falciparum*”. In: *Nature* 407.6807 (Oct. 2000), pp. 1018–1022. DOI: 10.1038/35039531. URL: <https://doi.org/10.1038/35039531>.

- [15] Malcolm J. Gardner et al. “Genome sequence of the human malaria parasite *Plasmodium falciparum*”. In: *Nature* 419.6906 (Oct. 2002), pp. 498–511. DOI: 10.1038/nature01097. URL: <https://doi.org/10.1038/nature01097>.
- [16] Tim-Wolf Gilberger et al. “A Novel Erythrocyte Binding Antigen-175 Parologue from *Plasmodium falciparum* Defines a New Trypsin-resistant Receptor on Human Erythrocytes”. In: *Journal of Biological Chemistry* 278.16 (Apr. 2003), pp. 14480–14486. DOI: 10.1074/jbc.m211446200. URL: <https://doi.org/10.1074/jbc.m211446200>.
- [17] Paul R. Gilson et al. “Identification and Stoichiometry of Glycosylphosphatidylinositol-anchored Membrane Proteins of the Human Malaria Parasite *Plasmodium falciparum*”. In: *Molecular & Cellular Proteomics* 5.7 (July 2006), pp. 1286–1299. DOI: 10.1074/mcp.m600035-mcp200. URL: <https://doi.org/10.1074/mcp.m600035-mcp200>.
- [18] Claire Gondeau et al. “The C-terminal domain of *Plasmodium falciparum* merozoite surface protein 3 self-assembles into alpha-helical coiled coil tetramer”. In: *Molecular and biochemical parasitology* 165.2 (June 2009), pp. 153–161. ISSN: 0166-6851. DOI: 10.1016/j.molbiopara.2009.01.015. URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680791/> (visited on 08/26/2021).
- [19] Karthigayan Gunalan et al. “The role of the reticulocyte-binding-like protein homologues of *Plasmodium* in erythrocyte sensing and invasion”. In: *Cellular Microbiology* 15.1 (Nov. 2012), pp. 35–44. DOI: 10.1111/cmi.12038. URL: <https://doi.org/10.1111/cmi.12038>.
- [20] Andrew J Guy et al. “BioStructMap: A Python tool for integration of protein structure and sequence-based features”. In: *Bioinformatics* (June 2018). Ed. by Alfonso Valencia. DOI: 10.1093/bioinformatics/bty474. URL: <https://doi.org/10.1093/bioinformatics/bty474>.
- [21] Andrew J. Guy et al. “Proteome-wide mapping of immune features onto *Plasmodium* protein three-dimensional structures”. In: *Scientific Reports* 8.1 (Mar. 2018). DOI: 10.1038/s41598-018-22592-3. URL: <https://doi.org/10.1038/s41598-018-22592-3>.
- [22] T J Hadley et al. “*Falciparum* malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion.” In: *Journal of*

- Clinical Investigation* 80.4 (Oct. 1987), pp. 1190–1193. DOI: 10.1172/jci113178. URL: <https://doi.org/10.1172/jci113178>.
- [23] Philippa K Harris et al. “Molecular Identification of a Malaria Merozoite Surface Sheddase”. In: *PLoS Pathogens* 1.3 (Nov. 2005). Ed. by David Samuel Schneider, e29. DOI: 10.1371/journal.ppat.0010029. URL: <https://doi.org/10.1371/journal.ppat.0010029>.
- [24] Anthony N. Hodder et al. “Insights into Duffy Binding-like Domains through the Crystal Structure and Function of the Merozoite Surface Protein MSPDBL2 from *Plasmodium falciparum*”. In: *Journal of Biological Chemistry* 287.39 (Sept. 2012), pp. 32922–32939. DOI: 10.1074/jbc.M112.350504. URL: <https://doi.org/10.1074/jbc.M112.350504>.
- [25] Hideyuki Iriko et al. “Diversity and evolution of the rhoph1/clag multi-gene family of *Plasmodium falciparum*”. In: *Molecular and Biochemical Parasitology* 158.1 (Mar. 2008), pp. 11–21. DOI: 10.1016/j.molbiopara.2007.11.004. URL: <https://doi.org/10.1016/j.molbiopara.2007.11.004>.
- [26] Ewa Jaskiewicz et al. “Erythrocyte glycoporins as receptors for *Plasmodium merozoites*”. In: *Parasites & Vectors* 12.1 (June 2019). DOI: 10.1186/s13071-019-3575-8. URL: <https://doi.org/10.1186/s13071-019-3575-8>.
- [27] Björn F. C. Kafsack et al. “A transcriptional switch underlies commitment to sexual development in malaria parasites”. In: *Nature* 507.7491 (Feb. 2014), pp. 248–252. DOI: 10.1038/nature12920. URL: <https://doi.org/10.1038/nature12920>.
- [28] Susan M Kraemer and Joseph D Smith. “A family affair: var genes, PfEMP1 binding, and malaria disease”. In: *Current Opinion in Microbiology* 9.4 (Aug. 2006), pp. 374–380. DOI: 10.1016/j.mib.2006.06.006. URL: <https://doi.org/10.1016/j.mib.2006.06.006>.
- [29] Susan M. Kraemer and Joseph D. Smith. “Evidence for the importance of genetic structuring to the structural and functional specialization of the *Plasmodium falciparum* var gene family”. In: *Molecular Microbiology* 50.5 (Nov. 2003), pp. 1527–1538. DOI: 10.1046/j.1365-2958.2003.03814.x. URL: <https://doi.org/10.1046/j.1365-2958.2003.03814.x>.

- [30] Clara S. Lin et al. “The Merozoite Surface Protein 1 Complex Is a Platform for Binding to Human Erythrocytes by *Plasmodium falciparum*”. In: *Journal of Biological Chemistry* 289.37 (Sept. 2014), pp. 25655–25669. DOI: 10.1074/jbc.m114.586495. URL: <https://doi.org/10.1074/jbc.m114.586495>.
- [31] Cheryl-Ann Lobo et al. “Glycophorin C is the receptor for the *Plasmodium falciparum* erythrocyte binding ligand PfEBP-2 (baebl)”. In: *Blood* 101.11 (June 2003), pp. 4628–4631. DOI: 10.1182/blood-2002-10-3076. URL: <https://doi.org/10.1182/blood-2002-10-3076>.
- [32] Sash Lopaticki et al. “Reticulocyte and Erythrocyte Binding-Like Proteins Function Cooperatively in Invasion of Human Erythrocytes by Malaria Parasites”. In: *Infection and Immunity* 79.3 (Mar. 2011). Ed. by J. H. Adams, pp. 1107–1117. DOI: 10.1128/iai.01021-10. URL: <https://doi.org/10.1128/iai.01021-10>.
- [33] Jose-Juan Lopez-Rubio, Liliana Mancio-Silva, and Artur Scherf. “Genome-wide Analysis of Heterochromatin Associates Clonally Variant Gene Regulation with Perinuclear Repressive Centers in Malaria Parasites”. In: *Cell Host & Microbe* 5.2 (Feb. 2009), pp. 179–190. DOI: 10.1016/j.chom.2008.12.012. URL: <https://doi.org/10.1016/j.chom.2008.12.012>.
- [34] Sorina Maciuca. “Analysis of complex genetic variation using population reference graphs”. en. PhD thesis. University of Oxford, 2017.
- [35] D. C. Ghislaine Mayer et al. “Characterization of a *Plasmodium falciparum* erythrocyte-binding protein paralogous to EBA-175”. In: *Proceedings of the National Academy of Sciences* 98.9 (2001), pp. 5222–5227. ISSN: 0027-8424. DOI: 10.1073/pnas.081075398. eprint: <https://www.pnas.org/content/98/9/5222.full.pdf>. URL: <https://www.pnas.org/content/98/9/5222>.
- [36] Damian J. McColl et al. “Molecular variation in a novel polymorphic antigen associated with *Plasmodium falciparum* merozoites”. In: *Molecular and Biochemical Parasitology* 68.1 (1994), pp. 53–67. ISSN: 0166-6851. DOI: [https://doi.org/10.1016/0166-6851\(94\)00149-9](https://doi.org/10.1016/0166-6851(94)00149-9). URL: <https://www.sciencedirect.com/science/article/pii/0166685194001499>.

- [37] LH Miller et al. “Erythrocyte receptors for (*Plasmodium knowlesi*) malaria: Duffy blood group determinants”. In: *Science* 189.4202 (1975), pp. 561–563. ISSN: 0036-8075. DOI: 10.1126/science.1145213. eprint: <https://science.sciencemag.org/content/189/4202/561.full.pdf>. URL: <https://science.sciencemag.org/content/189/4202/561>.
- [38] Louis H. Miller et al. “The pathogenic basis of malaria”. In: *Nature* 415.6872 (Feb. 2002), pp. 673–679. DOI: 10.1038/415673a. URL: <https://doi.org/10.1038/415673a>.
- [39] GH Mitchell et al. “Invasion of erythrocytes by *Plasmodium falciparum* malaria parasites: evidence for receptor heterogeneity and two receptors”. In: *Blood* 67.5 (May 1986), pp. 1519–1521. DOI: 10.1182/blood.v67.5.1519.1519. URL: <https://doi.org/10.1182/blood.v67.5.1519.1519>.
- [40] Rebecca A. O’Donnell et al. “Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite”. In: *Journal of Cell Biology* 174.7 (Sept. 2006), pp. 1023–1033. DOI: 10.1083/jcb.200604136. URL: <https://doi.org/10.1083/jcb.200604136>.
- [41] Lynette Isabella Ochola et al. “Allele Frequency–Based and Polymorphism–Versus–Divergence Indices of Balancing Selection in a New Filtered Set of Polymorphic Genes in *Plasmodium falciparum*”. en. In: *Molecular Biology and Evolution* 27.10 (Oct. 2010). Publisher: Oxford Academic, pp. 2344–2351. ISSN: 0737-4038. DOI: 10.1093/molbev/msq119. URL: <https://academic.oup.com/mbe/article/27/10/2344/967205> (visited on 10/26/2020).
- [42] P A Orlandi, F W Klotz, and J D Haynes. “A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of *Plasmodium falciparum* recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycoporphin A.” In: *Journal of Cell Biology* 116.4 (Feb. 1992), pp. 901–909. DOI: 10.1083/jcb.116.4.901. URL: <https://doi.org/10.1083/jcb.116.4.901>.
- [43] Faith H. A. Osier et al. “Breadth and Magnitude of Antibody Responses to Multiple *Plasmodium falciparum* Merozoite Antigens Are Associated with Protection from Clinical Malaria”. In: *Infection and*

- Immunity* 76.5 (May 2008), pp. 2240–2248. DOI: 10.1128/iai.01585-07. URL: <https://doi.org/10.1128/iai.01585-07>.
- [44] Thomas D. Otto et al. “Evolutionary analysis of the most polymorphic gene family in falciparum malaria”. en. In: *Wellcome Open Research* 4 (Dec. 2019), p. 193. ISSN: 2398-502X. DOI: 10.12688/wellcomeopenres.15590.1. URL: <https://wellcomeopenresearch.org/articles/4-193/v1> (visited on 09/14/2020).
- [45] Thomas D. Otto et al. “Genomes of all known members of a Plasmodium subgenus reveal paths to virulent human malaria”. In: *Nature Microbiology* 3.6 (May 2018), pp. 687–697. DOI: 10.1038/s41564-018-0162-2. URL: <https://doi.org/10.1038/s41564-018-0162-2>.
- [46] Thomas D. Otto et al. “New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq”. In: *Molecular Microbiology* 76.1 (Apr. 2010), pp. 12–24. DOI: 10.1111/j.1365-2958.2009.07026.x. URL: <https://doi.org/10.1111/j.1365-2958.2009.07026.x>.
- [47] Justin A. Pachebat et al. “The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7”. In: *Molecular and Biochemical Parasitology* 117.1 (Sept. 2001), pp. 83–89. DOI: 10.1016/s0166-6851(01)00336-x. URL: [https://doi.org/10.1016/s0166-6851\(01\)00336-x](https://doi.org/10.1016/s0166-6851(01)00336-x).
- [48] May M Paing et al. “Shed EBA-175 mediates red blood cell clustering that enhances malaria parasite growth and enables immune evasion”. In: *eLife* 7 (Dec. 2018). DOI: 10.7554/elife.43224. URL: <https://doi.org/10.7554/elife.43224>.
- [49] Asaf Poran et al. “Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites”. In: *Nature* 551.7678 (Sept. 2017), pp. 95–99. DOI: 10.1038/nature24280. URL: <https://doi.org/10.1038/nature24280>.
- [50] William R. Proto et al. “Adaptation of Plasmodium falciparum to humans involved the loss of an ape-specific erythrocyte invasion ligand”. In: *Nature Communications* 10.1 (Oct. 2019). DOI: 10.1038/s41467-019-12294-3. URL: <https://doi.org/10.1038/s41467-019-12294-3>.

- [51] Thomas S. Rask et al. “Plasmodium falciparum Erythrocyte Membrane Protein 1 Diversity in Seven Genomes – Divide and Conquer”. In: *PLoS Computational Biology* 6.9 (Sept. 2010). Ed. by Jonathan A. Eisen, e1000933. DOI: 10.1371/journal.pcbi.1000933. URL: <https://doi.org/10.1371/journal.pcbi.1000933>.
- [52] David J. Roberts et al. “Rapid switching to multiple antigenic and adhesive phenotypes in malaria”. In: *Nature* 357.6380 (June 1992), pp. 689–692. DOI: 10.1038/357689a0. URL: <https://doi.org/10.1038/357689a0>.
- [53] Hirokazu Sakamoto et al. “Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes”. In: *Vaccine* 30.11 (Mar. 2012), pp. 1972–1980. DOI: 10.1016/j.vaccine.2012.01.010. URL: <https://doi.org/10.1016/j.vaccine.2012.01.010>.
- [54] B K Sim et al. “Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion.” In: *Journal of Cell Biology* 111.5 (Nov. 1990), pp. 1877–1884. DOI: 10.1083/jcb.111.5.1877. URL: <https://doi.org/10.1083/jcb.111.5.1877>.
- [55] Subhash Singh et al. “A Conserved Multi-Gene Family Induces Cross-Reactive Antibodies Effective in Defense against Plasmodium falciparum”. en. In: *PLoS ONE* 4.4 (Apr. 2009). Ed. by Vasee Moorthy, e5410. ISSN: 1932-6203. DOI: 10.1371/journal.pone.0005410. URL: <https://dx.plos.org/10.1371/journal.pone.0005410> (visited on 08/24/2021).
- [56] Joseph D Smith et al. “Classification of adhesive domains in the Plasmodium falciparum Erythrocyte Membrane Protein 1 family”. In: *Molecular and Biochemical Parasitology* 110.2 (Oct. 2000), pp. 293–310. DOI: 10.1016/S0166-6851(00)00279-6. URL: [https://doi.org/10.1016/S0166-6851\(00\)00279-6](https://doi.org/10.1016/S0166-6851(00)00279-6).
- [57] J. Stubbs. “Molecular Mechanism for Switching of P. falciparum Invasion Pathways into Human Erythrocytes”. In: *Science* 309.5739 (Aug. 2005), pp. 1384–1387. DOI: 10.1126/science.1115257. URL: <https://doi.org/10.1126/science.1115257>.

- [58] X. Su. “A Genetic Map and Recombination Parameters of the Human Malaria Parasite *Plasmodium falciparum*”. In: *Science* 286.5443 (Nov. 1999), pp. 1351–1353. DOI: 10.1126/science.286.5443.1351. URL: <https://doi.org/10.1126/science.286.5443.1351>.
- [59] Xin-zhuan Su et al. “The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes”. In: *Cell* 82.1 (July 1995), pp. 89–100. DOI: 10.1016/0092-8674(95)90055-1. URL: [https://doi.org/10.1016/0092-8674\(95\)90055-1](https://doi.org/10.1016/0092-8674(95)90055-1).
- [60] Kevin K. A. Tetteh et al. “Prospective Identification of Malaria Parasite Genes under Balancing Selection”. In: *PLoS ONE* 4.5 (May 2009). Ed. by Denise L. Doolan, e5568. DOI: 10.1371/journal.pone.0005568. URL: <https://doi.org/10.1371/journal.pone.0005568>.
- [61] Niraj H. Tolia et al. “Structural Basis for the EBA-175 Erythrocyte Invasion Pathway of the Malaria Parasite *Plasmodium falciparum*”. In: *Cell* 122.2 (July 2005), pp. 183–193. DOI: 10.1016/j.cell.2005.05.033. URL: <https://doi.org/10.1016/j.cell.2005.05.033>.
- [62] Carlotta Trucco et al. “The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the *Plasmodium falciparum* merozoite surface protein-1 complex”. In: *Molecular and Biochemical Parasitology* 112.1 (Jan. 2001), pp. 91–101. DOI: 10.1016/S0166-6851(00)00350-9. URL: [https://doi.org/10.1016/S0166-6851\(00\)00350-9](https://doi.org/10.1016/S0166-6851(00)00350-9).
- [63] Daria Van Tyne et al. “Identification and Functional Validation of the Novel Antimalarial Resistance Locus PF10_0355 in *Plasmodium falciparum*”. In: *PLoS Genetics* 7.4 (Apr. 2011). Ed. by Nancy A. Moran, e1001383. DOI: 10.1371/journal.pgen.1001383. URL: <https://doi.org/10.1371/journal.pgen.1001383>.
- [64] Daria Van Tyne et al. “Modulation of PF10_0355 (MSPDBL2) Alters *Plasmodium falciparum* Response to Antimalarial Drugs”. In: *Antimicrobial Agents and Chemotherapy* 57.7 (Apr. 2013), pp. 2937–2941. DOI: 10.1128/aac.02574-12. URL: <https://doi.org/10.1128/aac.02574-12>.
- [65] Thilan Wickramarachchi et al. “A novel *Plasmodium falciparum* erythrocyte binding protein associated with the merozoite surface, PfDBLMSP”. In: *International Journal for Parasitology* 39.7 (June

2009), pp. 763–773. ISSN: 0020-7519. DOI: 10.1016/j.ijpara.2008.12.004. URL: <https://www.sciencedirect.com/science/article/pii/S0020751909000253> (visited on 08/24/2021).

- [66] **Gavin J. Wright and Julian C. Rayner.** “**Plasmodium falciparum Erythrocyte Invasion: Combining Function with Immune Evasion**”. In: *PLoS Pathogens* 10.3 (Mar. 2014), e1003943. DOI: 10.1371/journal.ppat.1003943. URL: <https://doi.org/10.1371/journal.ppat.1003943>.